sonnet biotherapeutics stock predictions

Sonnet Biotherapeutics Holdings s revenue in 2022 is 770816. Is Sonnet BioTherapeutics Holdings Stock Undervalued.

Sonn Stock Price Forecast Should You Buy Sonn

The analyst firm set a price target for.

. The latest price target for Sonnet BioTherapeutics NASDAQ. At Sonnet BioTherapeutics we are taking the fight directly to cancer. According to the issued ratings of 3 analysts in the last year the consensus rating for Sonnet BioTherapeutics stock is Buy based on the current 3 buy ratings for SONN.

Sonnet BioTherapeutics Holdings Inc an oncology-focused biotechnology company develops platform for biologic medicines of single or bispecific action. NASDAQSONNs beta value is holding at 099 while the average true range ATR indicator is currently reading 032. The award for todays most impressive mover has to go to Sonnet BioTherapeutics NASDAQ.

The current Sonnet BioTherapeutics Holdings SONN share price is 114. The average Sonnet BioTherapeutics Holdings stock forecast 2023 represents a 061 increase from the last price of 147000002861023. The target price for SONN stock is 28 based on the average of what a group of analyst think SONN stock could be worth at a future date.

Sonnet BioTherapeutics Holdings Inc. Currently SONN stock has surged more than 120 on an intraday move. For Sonnet BioTherapeutics Holdings stock.

Shares will drop by -735and reach 0255170 per share by. The company develops fully. Powering a New Wave of Immune Therapeutics.

Our proprietary F H AB Fully Human Albumin Binding technology. 130 rows As of 2022 October 19 Wednesday current price of SONN stock is 1290 and our data indicates that the asset price has been in an uptrend for the past 1 year or since its. According to our current SONN stock forecast the value of Sonnet BioTherapeutics Holdings Inc.

The average price target for Sonnet BioTherapeutics Holdings is 2200. Our latest prediction for Sonnet BioTherapeutics Holdings Incs stock price was made on the June 9 2021 when the stock price was at 153. The company develops fully.

This is based on 1 Wall Streets Analysts 12-month price targets issued in the past 3 months. The highest analyst price. On average 1 Wall Street analysts forecast SONNs revenue for 2023 to be 432771 with the lowest SONN revenue.

Sonnet BioTherapeutics Holdings Inc a clinical stage oncology-focused biotechnology company develops platform for biologic medicines of single or bispecific. SONN was reported by Chardan Capital on September 22 2022. In the short term 2weeks.

Sonnet BioTherapeutics Holdings Stock Forecast. Sonnet BioTherapeutics Holdings Inc an oncology-focused biotechnology company develops platform for biologic medicines of single or bispecific action. The company develops fully.

Sonnet BioTherapeutics Holdings Inc an oncology-focused biotechnology company develops platform for biologic medicines of single or bispecific action.

Sonnet Biotherapeutics Stock Nasdaq Sonn Quotes And News Summary Benzinga